AlzChem Group (ACT) H2 2025 earnings summary

Executive summary

• Achieved consolidated sales of EUR 562.1 million in 2025, near the forecasted EUR 580 million, with 2% revenue growth and 11% EBITDA growth year-over-year, outperforming a challenging European chemical environment.

• Group EBITDA rose 11% to EUR 116.5 million, exceeding guidance, with a record EBITDA margin of 20.7%.

• Net income increased 17% to EUR 64 million, supporting a proposed 17% dividend increase to EUR 2.10 per share.

• Specialty chemicals segment drove growth, especially in human nutrition and defense, offsetting declines in basic/intermediate chemicals.

• Major investments in creatine and nitroguanidine capacity expansions, including a EUR 120 million creatine plant, are set to fuel future growth.

Financial highlights

• Sales increased by EUR 8 million year-over-year to EUR 562.1 million, with strongest growth in the U.S. and Europe.

• EBITDA grew by EUR 11 million to EUR 116.5 million, outpacing sales growth due to higher-margin specialty products.

• Net income reached EUR 64 million, up 18% year-over-year; EPS increased 18.3% to EUR 6.28.

• Operating cash flow rose 30% to EUR 137 million, benefiting from EUR 60 million in customer grants and higher working capital.

• Maintained a positive net cash position of EUR 31 million at year-end; cash and cash equivalents increased to EUR 71.7 million.

Outlook and guidance

• 2026 sales expected to reach EUR 600 million (+7%), with EBITDA forecast at EUR 126 million (+8%).

• Growth to be driven organically, especially by specialty chemicals, human nutrition, and defense.

• Major capacity expansions in creatine and nitroguanidine to support double-digit growth in 2027.

• Maintenance shutdown of a carbide furnace in H1 2026 will impact EBITDA by approx. EUR 15 million.

• Free cash flow expected to be around zero in 2026 due to high CapEx and customer prepayments.